Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 2NIH 2

Study Type

Observational 6Interventional 4

Sponsor

Cancer Type

Genitourinary 4Sarcoma 1Gynecologic 1Breast 1

Conditions

Rectal Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Colonic Neoplasms 6Prostatic Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Colorectal Neoplasms 4Burkitt Lymphoma 4Breast Neoplasms 4Waldenstrom Macroglobulinemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Extranodal NK-T-Cell 3Congenital Abnormalities 3Unspecified Adult Solid Tumor, Protocol Specific 2Stomach Neoplasms 2Sezary Syndrome 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2

Interventions

Docetaxel 277Prednisone 236enzalutamide 175Leuprolide 172Radiotherapy 164Abiraterone Acetate 153Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 78abiraterone 75gallium 68 PSMA-11 74Specimen Handling 67Gonadotropin-Releasing Hormone 58darolutamide 56Radiation 56Triptorelin Pamoate 53cabazitaxel 49Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT01083368 2019-08-21

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Case Comprehensive Cancer Center

Phase 1/2 Completed
22 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT00089609 2018-04-20

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
73 enrolled 16 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01338792 2014-03-10

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

University of Southern California

Phase 2 Completed
47 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00601406 2013-08-26

Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer

National Cancer Institute (NCI)

Phase NA Unknown
2,200 enrolled
BreastGenitourinaryGynecologicSarcoma

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡